未來展望及研究方向

本研究中已有轉移之病人，手術與否在病人存活上並未達到統計上之顯著差異。然而因本研究中 已有轉移之病人僅 74 位，其中 29 位接受手術治療，而 45 位未接受手術治療，故未顯示統計顯著差 異之結果有可能是因轉移病人在手術變數各分群之人數太小，以致統計力不足，無法顯示出差異。故 未來應針對上泌尿道上皮癌病人已轉移者，進行一研究收錄更多病人，來回答此問題。此外，對於女 性為何在上泌尿道上皮侵襲癌之存活較佳之可能原因，亦尚待進一步研究來釐清。ICD 碼在上泌尿道 上皮癌之登錄碼甚多，但只有發生於單一器官之上泌尿道上皮癌之 ICD 登錄碼(如:189.1 或 C65.9 表 腎盂癌，189.2 或 C66.9 表輸尿管癌)，可由 ICD 碼得知上泌尿道上皮癌發生之器官部位，其餘表達發 生於多器官之泌尿道上皮癌之 ICD 登錄碼(如 189.8 或 C68.8 表連續性跨器官之泌尿上皮癌，189.9 或 C68.9 表未明示位置之上皮癌) ，皆無法由 ICD 碼得知泌尿道上皮癌發生之器官部位，故應發展合適 的編碼系統，以期達到既能分類，也能得知癌症發生器官位置之實用性。

參考文獻

1. Yu DS: Update on urothelial carcinoma. In: Clinical Urology, 1st ed. Edited by Kuo HC, Lai MK, Yang CR et al. Taiwan: Taiwan Urological Association, vol. 2, pp. 1372-1384, 2012

2. Huang PC, Yu HJ: Urothelial carcinoma of the upper urinary tract. In: Clinical Urology, 1st ed. Edited by Kuo HC, Lai MK, Yang CR et al. Taiwan: Taiwan Urological Association, vol. 2, pp. 1385-1392, 2012 3. Wu MM: Renal cancer. In: Epidemiological characteristics and preventive strategies of cancers in Taiwan, 1st ed. Edited by Chen CJ and C. KY. Taiwan: S. Y. Dao Cancer Prevention Foundation, pp. 102-120, 2011 4. Munoz JJ, Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.

J Urol, 2000; 164: 1523.

5. Mellemgaard A, Carstensen B, Norgaard N et al: Trends in the incidence of cancer of the kidney, pelvis, ureter and bladder in Denmark 1943-88. Scand J Urol Nephrol, 1993; 27: 327.

6. Cancer Incidence in Five Continents. Edited by M. P. Curado, B. Edwards, H. R. Shin et al. Lyon, France:

International Agency for Research on Cancer, World Health Organization, vol. IX, pp. p590-597, 2007 7. Chow WH, Dong LM, Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol, 2010;

7: 245.

8. Wihlborg A, Johansen C: Incidences of kidney, pelvis, ureter, and bladder cancer in a nationwide, population-based cancer registry, Denmark, 1944-2003. Urology, 2010; 75: 1222.

9. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol, 2003; 47: 155.

10. Ouzzane A, Colin P, Xylinas E et al: Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol, 2011; 60: 1258.

11. Roupret M, Zigeuner R, Palou J et al: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol, 2011; 59: 584.

12. Taiwan Cancer Registry Interactive Query. Data access on April, 19th, 2016 via http://

cris.hpa.gov.tw/pagepub/Home.aspx

13. Garne JP, Aspegren K, Moller T: Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971-1991. Acta Oncol, 1995; 34: 153.

14. Bray F, Parkin DM: Evaluation of data quality in the cancer registry: principles and methods. Part I:

comparability, validity and timeliness. Eur J Cancer, 2009; 45: 747.

15. Hall S, Schulze K, Groome P et al: Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol, 2006; 59: 67.

16. Cheng CL, Lee CH, Chen PS et al: Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol, 2014; 24: 500.

17. Holmang S, Amsler-Nordin S, Carlson K et al: Completeness and correctness of registration of renal pelvic and ureteral cancer in the Swedish Cancer Registry. Scand J Urol Nephrol, 2008; 42: 12.

18. Holmang S, Hedelin H, Anderstrom C et al: Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two-year period. Scand J Urol Nephrol, 2000; 34:

95.

19. Korhonen P, Malila N, Pukkala E et al: The Finnish Cancer Registry as follow-up source of a large trial cohort--accuracy and delay. Acta Oncol, 2002; 41: 381.

20. Oosterlinck W, Solsona E, van der Meijden AP et al: EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol, 2004; 46: 147.

21. Charbit L, Gendreau MC, Mee S et al: Tumors of the upper urinary tract: 10 years of experience. J Urol, 1991; 146: 1243.

22. Hall MC, Womack S, Sagalowsky AI et al: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology, 1998; 52: 594.

23. Huben RP, Mounzer AM, Murphy GP: Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer, 1988; 62: 2016.

24. Kakizoe T, Fujita J, Murase T et al: Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. J Urol, 1980; 124: 17.

25. Krogh J, Kvist E, Rye B: Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences. Br J Urol, 1991; 67: 32.

26. Racioppi M, D'Addessi A, Alcini A et al: Clinical review of 100 consecutive surgically treated patients with upper urinary tract transitional tumours. Br J Urol, 1997; 80: 707.

27. Chen WJ, Kuo JY, Chen KK et al: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc, 2005; 68: 522.

28. Tan LB, Chang LL, Cheng KI et al: Transitional cell carcinomas of the renal pelvis and the ureter:

comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU Int, 2009; 103: 312.

29. Chen CY, Liao YM, Tsai WM et al: Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease. J Formos Med Assoc, 2007; 106: 992.

30. Favaretto RL, Shariat SF, Chade DC et al: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol, 2010; 58: 574.

31. Li CC, Chang TH, Wu WJ et al: Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol, 2008; 54: 1127.

32. Li WM, Li CC, Ke HL et al: The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol, 2009; 182: 451.

33. Olgac S, Mazumdar M, Dalbagni G et al: Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol, 2004; 28: 1545.

34. Chromecki TF, Cha EK, Fajkovic H et al: The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol, 2012; 61: 245.

35. Kang CH, Yu TJ, Hsieh HH et al: The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer, 2003; 98: 1620.

36. Papatsoris AG, Chrisofos M, Skolarikos A et al: Upper urinary tract transitional cell carcinoma. A 10-year experience. Tumori, 2008; 94: 75.

upper tract urothelial carcinoma. Urol Oncol, 2013; 31: 1161.

38. Yafi FA, Novara G, Shariat SF et al: Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int, 2012; 110: E7.

39. Bethesda MD: Multiple primary and histology coding rules: National Cancer Institute, Surveillance Epidemiology and End Results Program, 2007

40. Fritz A, Percy C, Jack A et al: International Classification of Diseases for Oncology, 3rd ed. Geneva:

World Health Organization, 2000

41. Amin MB: Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol, 2009; 22 Suppl 2: S96.

42. Nigwekar P, Amin MB: The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol, 2008; 15: 218.

43. Zhai QJ, Black J, Ayala AG et al: Histologic variants of infiltrating urothelial carcinoma. Arch Pathol Lab Med, 2007; 131: 1244.

44. Lopez-Beltran A, Martin J, Garcia J et al: Squamous and glandular differentiation in urothelial bladder carcinomas. Histopathology, histochemistry and immunohistochemical expression of carcinoembryonic antigen. Histol Histopathol, 1988; 3: 63.

45. Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol, 2009; 27: 3.

46. Roupret M, Babjuk M, Comperat E et al: European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol, 2015; 68: 868.

附錄

附錄一：上皮癌之組織型態類別與癌症登記編碼

組織型態類別 癌症登記編碼

papillary carcinoma, papillary transitional cell carcinoma 8130 With squamous, glandular or trophoblastic differentiation, nested

carcinoma, microcystic carcinoma, unspecified transitional cell carcinoma

8120

Micropapillary carcinoma 8131

Lymphoepithelioma-like carcinoma, plasmacytoid carcinoma 8082

Giant cell carcinoma 8031

Sarcomatoid carcinoma 8122

Undifferentiated carcinoma 8020

From: Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK. The 2007 Multiple Primary and Histology Coding Rules. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD, 2007 ³⁹